Published in Biochem J on February 15, 2003
Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res (2003) 9.30
Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A (2004) 1.91
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget (2015) 0.98
Surfing the p53 network. Nature (2000) 35.36
Mitochondria and apoptosis. Science (1998) 23.41
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell (1993) 20.72
Caspases: enemies within. Science (1998) 19.45
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
BCL-2 family members and the mitochondria in apoptosis. Genes Dev (1999) 13.52
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (1994) 10.22
Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol (1997) 9.18
Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A (1997) 7.25
Structure of Bax: coregulation of dimer formation and intracellular localization. Cell (2000) 7.00
Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A (1998) 6.69
Inhibition of Bax channel-forming activity by Bcl-2. Science (1997) 5.10
Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J (1999) 5.10
p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature (1994) 4.77
Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci U S A (1995) 4.22
A small-scale procedure for preparation of nuclear extracts that support efficient transcription and pre-mRNA splicing. Gene Anal Tech (1989) 3.95
Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci U S A (1997) 3.66
Regulation of the p53 tumor suppressor protein. J Biol Chem (1999) 2.94
The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J (1996) 2.71
Bcl-2 and Bax function independently to regulate cell death. Nat Genet (1997) 2.64
Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Biochem J (1996) 2.46
The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J (1997) 2.44
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 1.99
Caspases disrupt the nuclear-cytoplasmic barrier. J Cell Biol (2000) 1.84
N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death. J Cell Biochem (2000) 1.80
Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem (1997) 1.78
Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res (2000) 1.73
Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta (1998) 1.65
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood (1998) 1.61
Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol (1999) 1.48
Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J Virol (1998) 1.38
Cleavage of Bax enhances its cell death function. Exp Cell Res (2000) 1.36
The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol (1998) 1.33
Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J Virol (1998) 1.28
Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc Natl Acad Sci U S A (1988) 1.24
Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene (1993) 1.23
p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J Biol Chem (1999) 1.22
Repression of bax gene expression by the HTLV-1 Tax protein: implications for suppression of apoptosis in virally infected cells. Virology (1997) 1.22
BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene (1998) 1.20
A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J (1998) 1.19
Bcl-2 and Bax proteins are present in interphase nuclei of mammalian cells. Cell Death Differ (2000) 1.10
Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis. Oncogene (2000) 1.09
Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms. Oncogene (1999) 1.08
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood (1998) 1.02
Suppression of interleukin-2 and interleukin-2 receptor expression in Jurkat cells stably expressing the human immunodeficiency virus Tat protein. Cell Immunol (1992) 0.98
Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood (2001) 0.96
Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res (1996) 0.96
Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene (1998) 0.94
Inhibition of caspase cascade by HTLV-I tax through induction of NF-kappaB nuclear translocation. Blood (1999) 0.92
Nuclear translocation and increased expression of Bax and disturbance in cell cycle progression without prominent apoptosis induced by hyperthermia. Exp Cell Res (1998) 0.91
DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol (1998) 0.88
IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors. J Immunol (1988) 0.87
Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett (1999) 0.81
GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis (2000) 0.80
Structural association of Bax with nuclear matrix and cytomatrix revealed by embedment-free immunogold electron microscopy. Cell Biol Int (2000) 0.80
Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.02
WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol (2009) 2.36
GDNF family receptor alpha1 phenotype of spermatogonial stem cells in immature mouse testes. Biol Reprod (2005) 1.71
C6ORF66 is an assembly factor of mitochondrial complex I. Am J Hum Genet (2008) 1.56
mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. Cell Reprogram (2010) 1.21
LifeMap Discovery™: the embryonic development, stem cells, and regenerative medicine research portal. PLoS One (2013) 1.14
Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anticancer Ther (2004) 1.03
TAT-based drug delivery system--new directions in protein delivery for new hopes? Expert Opin Drug Deliv (2009) 1.01
Female sex bias in human embryonic stem cell lines. Stem Cells Dev (2011) 0.99
Let-7d microRNA affects mesenchymal phenotypic properties of lung fibroblasts. Am J Physiol Lung Cell Mol Physiol (2014) 0.95
Derivation and characterization of nonhuman primate embryonic stem cells. Curr Protoc Stem Cell Biol (2007) 0.92
Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-alpha, IL-6 and IL-1 beta: possible relevance to multiple sclerosis. J Neuroimmunol (2003) 0.91
Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency. J Mol Med (Berl) (2010) 0.89
Human amniotic epithelial cells are reprogrammed more efficiently by induced pluripotency than adult fibroblasts. Cell Reprogram (2012) 0.88
TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol Ther (2008) 0.86
Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells. Mol Med (2013) 0.85
α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease. PLoS One (2011) 0.84
Semiquantitative histopathology and 3D magnetic resonance microscopy as collaborative platforms for tissue identification and comparison within teratomas derived from pedigreed primate embryonic stem cells. Stem Cell Res (2010) 0.84
A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria. J Biol Chem (2007) 0.81
Establishment and characterization of baboon embryonic stem cell lines: an Old World Primate model for regeneration and transplantation research. Stem Cell Res (2009) 0.81
IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis. Int Immunopharmacol (2009) 0.80
Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactions. Clin Immunol (2004) 0.79
Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury. Int J Exp Pathol (2005) 0.79
Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res (2003) 0.79
Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins. Biochem Biophys Res Commun (2002) 0.77
Nicotine exposure during differentiation causes inhibition of N-myc expression. Respir Res (2013) 0.76
IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway. Int J Cancer (2011) 0.76
A fusion protein composed of IL-2 and caspase-3 ameliorates the outcome of experimental inflammatory colitis. Ann N Y Acad Sci (2009) 0.75
Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma. Int J Oncol (2005) 0.75
Sexually dimorphic gene expression in non-human primate ESCs analyzed stringently. Biochem Biophys Res Commun (2011) 0.75
Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies. Cancer (2012) 0.75
Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric protein. Biotechnol Prog (2012) 0.75